Page 17 - DIFDUF
P. 17

703
                                                                                                    with normative data, silicone implants are associated with
                                                                                                    resonance imaging surveillance was under 5%. Compared
 PERFECTOR
                                                                                                    silicone for primary augmentation. Long-term magnetic
                                                                                                    data included  99,993 patients,  56% of implants were
                                                                                                    and operative indication in the short and long terms. LPAS
                                                                                                    related complications were analyzed by implant composition
                                                                                                    outcomes were compared with normative data. Implant-
                                                                                                    reconstruction. Systemic harms, self-harm, and reproductive
                                                                                                    and Mentor) placed for primary/revision augmentation/
                                                                                                    silicone/saline implants from two manufacturers (Allergan
                                                                                                    long-term implant-related outcomes and systemic harms for
                                                                                                    postapproval studies (LPAS) prospectively have monitored
                                                                                                    efficacy outcomes of patients with breast implants. Long
                                                                                                    Coroneos and co-authors analyzed the long-term safety and
                                                                                                    long-term outcomes of silicone breast implants
                                                                                                    Capsule
                                                                                                    pancreatic tumors sampled. Ablating DKK3, either by genetic
                                                                                                    stellate cells. This protein was present in the majority of human
                                                                                                    therapeutic target called DKK3, which is produced by pancreatic
                                                                                                    themselves rather than the stroma. zhou et al. identified a
                                                                                                    as for its dense stroma. Most therapies target the tumor cells
                                                                                                    Pancreatic cancer is infamous for its bad prognosis as well
                                                                                                    Killing tumors by targeting their neighbors
                                                                                                    Capsule
                                                                                                    Nature 2009; 461: 199-205.
                                                                                                      16.  Visel A, Rubin EM, Pennacchio LA. Genomic views of distant-acting enhancers.
                                                                                                    Soc 2006; 128: 8868-74.
                                                                                                    targeting the allosteric mechanism of the thyroid hormone receptor. J Am Chem
                                                                                                      15.  Hassan AQ, Koh JT. A functionally orthogonal ligand-receptor pair created by
                                                                                                    release and negative transcriptional regulation. Mol Endocrinol 1998; 12: 609-21.
                                                                                                    in resistance to thyroid hormone syndrome predominantly impairs corepressor
                                                                                                      14.  Clifton-Bligh RJ, de Zegher F, Wagner RL, et al. A novel TR beta mutation (R383H)
                                                                                                    of thyroid hormone treatment. Eur J Endocrinol 2011; 165: 823-30.
                                                                                                    deletion in the monocarboxylate transporter 8 gene: 7-year follow-up and effects
 131118-COHANIM - 131118-COHANIM | 3 - A | 18-11-13 | 11:24:13 | SR:-- | Cyan
 #131118-COHANIM - 131118-COHANIM | 3 - A | 18-11-13 | 11:24:13 | SR:-- | Black
                                                                                                      13.  Zung A, Visser TJ, Uitterlinden AG, Rivadeneira F, Friesema EC. A child with a
 131118-COHANIM - 131118-COHANIM | 3 - A | 18-11-13 | 11:24:13 | SR:-- | Yellow
 131118-COHANIM - 131118-COHANIM | 3 - A | 18-11-13 | 11:24:13 | SR:-- | Magenta
                                                                                                    hormone receptor gene in an Israeli child. Thyroid 2003; 13: 409-12.
                                                                                                    resistance to thyroid hormone caused by a de novo P453T mutation in the thyroid
                                                                                                      12.  Ishay  A, Dumitrescu A,  Luboshitzky R, Rakover Y, Refetoff S. A new case of
                                                                                                    J Clin Endocrinol Metab 1982; 54: 76-82.
 KEY WORDS:
                                                                                                    inappropriate thyrotropin secretion successfully treated with triiodothyronine.
                                                                                                      11.  Rosler A, Litvin Y, Hage C, Gross J, Cerasi E. Familial hyperthyroidism due to
                                                                                                    Pediatr 2007; 50: 576-9.
                                                                                                    THRB gene in a Korean patient with resistance to thyroid hormone. Korean J
                                                                                                      10.  Shin JY, Ki C-S, Kim JK. Identification of a de novo mutation (H435Y) in the
                                                                                                    separate subtypes of resistance. J Clin Endocrinol Metab 1995; 80: 3613-6.
                                                                                                    hormone: two mutations of the same codon (H435L and H435Q) produce
                                                                                                    hormone receptor beta gene in unrelated patients with resistance to thyroid
                                                                                                      9.  Tsukaguchi H, Yoshimasa Y, Fujimoto K, et al. Three novel mutations of thyroid
                                                                                                    in the live-born population in Israel. IMAJ 2005; 7: 311-4.
                                                                                                      8.  Dollberg S, Haklai Z, Mimouni FB, Gorfein I, Gordon ES. Birth weight standards
 #
 EDITORIALS
 Case CommuniCations  The list cannot be completed without   In the early 1980s, four young pedia-  The third prominent physician in the   mentioning two other pediatricians who,   cyte adhesion deficiency syndromes [11].  focus was mainly on new forms of leuko-  for PID in Israel was created. His research   Jeffery Modell Foundation (JMF) center   Healthcare Campus in Haifa, where the first   group is Prof. Amos Etzioni from Rambam   disorders there [10]. The last one in
 the pregnancy. The patient began propyl-  according to their ligand binding capacity,   on interventions during gestation [1].   Clinical and Molecular Characteristics of Eight Israeli
 thiouracil treatment while waiting for the   but the clinical severity of the syndrome is   The appropriate management of pregnant
 results from the amniocentesis. The patient’s   not necessarily correlated with the degree   women with RTH is ideally based on the   families with Thyroid Hormone Receptor Beta Mutations
 thyroid function tests during the pregnancy   of functional impairment of the receptors.   prenatal identification of the fetal genotype
 and data on propylthiouracil treatment are   Moreover, significant differences in clinical   and on maternal thyroid function tests.   Eliyahu Zaig MD *, Odile Cohen-Ouaknine MD , Anat Tsur MD , Sheila Nagar MD , Gherta Bril MD , Lior Tolkin MD ,
                                                            2
                                                2
                                                                            2
                                                                                                        4
                                                                                          3
                       1
 shown in Table 1.   symptoms are observed in patients harbor-  Several situations may be encountered   Avivit Cahn MD , Mozhgan Heyman  and Benjamin Glaser MD 1
                                       1
                      1
 The fetus was found to be unaffected.   ing the same mutation [2].  in pregnant women with RTH. In a first
 Fetal development and well-being was   A characteristic feature of the syndrome   scenario, both the mother and the fetus   1 2 Departments of Endocrinology and Metabolism and of Internal Medicine, Hebrew University–Hadassah Medical School, Jerusalem, Israel
 assessed by prenatal ultrasound per-  is the preservation of the TSH response   harbor the same mutation. In this case, the   3 Endocrinology Unit, Clalit Health Services, Jerusalem, Israel
          Clalit Health Services, Tel Aviv, Israel
 formed at weeks 15, 23, 30, and 37.   to TRH despite elevated TH levels. In   fetus is resistant to TH and tolerates the   4 Department of Internal Medicine and Endocrine Unit, Shaare Zedek Medical Center, Jerusalem, Israel
 Cardiotocography for fetal heart rate   this respect, it is notable that our patient   high maternal TH levels. No treatment is
 assessment, performed at weeks 32 and 37,   underwent a TRH test twice. The first test   recommended during pregnancy.
 revealed normal heart rate with moderate   was under propylthiouracil treatment and   In a second scenario, a normal mother
 variability. Fetal thyroid ultrasound was per-  the results showed an exaggerated response   is carrying an affected fetus. Surprisingly,
 formed at week 34 and revealed a normal   of TSH, whereas the second time was with-  in this situation no increased rates of mis-  educed sensitivity to thyroid hormone (RSTH) syndrome is
 thyroid size according to the pregnancy age.  out propylthiouracil treatment and the   carriage or birth complications have been   ABSTRACT:  Background: Reduced sensitivity to thyroid hormone (RSTH)   R a heterogeneous group of defects characterized by impaired
 A healthy male infant was born at term.   results showed a very flat TSH slope with   observed. Such neonates, born to normal   syndrome describes a group of rare heterogeneous genetic   biological activity of intact thyroid hormones (THs). To date,
 His birth weight was 2930 g. Physical   maximum TSH 6 mIU/L after 15 minutes.   mothers and affected fathers, do not show   disorders. Precise diagnosis is essential to avoid unnecessary   three distinct clinical syndromes have been identified, each
 examination revealed a normal size ante-  In healthy euthyroid subjects, the mini-  symptoms of TH deprivation or elevations   treatment.  associated with defects in a different molecular process. The
 rior fontanelle, a symmetric head, normal   mum peak TSH following a TRH test is 5   of TSH.   Objectives: To identify and characterize patients previously   most common syndrome is resistance to thyroid hormone
 skin color, and normal heart examination.   mIU/L, whereas the maximum peak ranges   In a third scenario, the RTH mother   undiagnosed with RSTH in Israel.   (RTH), which is attributed to mutations in the thyroid receptor-
 Cord blood TSH concentration was 4.65   between 17.2 and 19.5 mIU/L.   has undergone previous ablative therapy   Methods: Patients with suspected RSTH throughout Israel were   beta (RTH-β) gene. The syndrome is characterized by decreased
 IU/ml (normal for reference range). The   We speculate that the results of the TRH   (radioiodine, surgery) or is affected by   referred for study. After clinical evaluation, genomic DNA was   sensitivity of target tissues to TH action, leading to elevated TH
 neonate did well without jaundice and was   test in our patient were probably related to   Hashimoto’s thyroiditis. In this situation,   obtained and all coding exons of the thyroid hormone receptor   levels, accompanied by normal or high thyroid-stimulating
 discharged on postpartum day 3.  a recent propylthiouracil treatment that she   the outcomes (birth weight, TSH at birth)   beta (THRB) gene were sequenced. If mutations were found,   hormone (TSH) values, with variable clinical manifestations [1].
 had received, which caused some degree of   are normal, whether the fetus harbors the   all available blood relatives were evaluated. The common   The molecular mechanism responsible for the clinical het-
                     polymorphism rs2596623, a putative intronic regulatory
 hypothyroidism.   mutation or not. In this case, it is suggested     erogeneity seen in RTH-β is unknown, but genetic or yet-to-
 COMMEnT  Due to a lack of prospective studies on   to maintain FT4 levels within a maximum   variant, was also genotyped. Genotype/phenotype correlations   be-discovered environmental factors modifying the mutant/
 RTH is a rare disorder characterized by   pregnant subjects with RTH, there are no   of 20% above the upper limit of normal   were sought, and the effect of mutation status on pregnancy   normal allele expression ratio in various target tissues may be
                     outcome was determined.
 reduced end-organ responsiveness to   definite recommendations for the man-  (ULN) [3].   Results: Eight mutations (one novel, two de-novo, six dominant)   responsible. One possible mechanism could be related to the
 TSH. The prevalence of the condition is   agement of pregnancy in women with this   A fourth scenario is illustrated by the   were identified in eight probands and 13 family members.   general observation that genes that are specifically expressed
 1:40,000 live births and is equal in both   condition. It is also unlikely that such stud-  case we report here. In this situation, a   Clinical and genetic features were similar to those reported   in different tissues may use alternative regulatory regions to
 genders [1]. The inheritance is autosomal   ies would be performed because this con-  normal fetus is carried by a woman with   in other populations. Previous suggestions that rs2596623   fine-tune tissue-specific expression. Cis-regulatory non-coding
 dominant. Autosomal recessive transmis-  dition is very uncommon and is often not   RTH. Consequently, the fetus is exposed   predicts clinical features were not confirmed. There was no   variants can reduce or increase allele-specific transcription in
 sion has been found in approximately 10%   diagnosed before pregnancy, as the patients   to incongruent high maternal TH levels,   evidence of increased risk of miscarriage or fetal viability.   a particular cell type, modifying disease risk or phenotype and
 of families; 15% of subjects with RTH have   are usually clinically euthyroid with normal   while the mother remains clinically euthy-  Mothers carrying a THRB mutation tended to have increased   thus contributing to the diversity in human genetic diseases.
 no detectable mutation in the TRβ gene [2].   TSH levels. There are sparse published data   roid.   gestational hypertension and low weight gain during   The thyroid hormone receptor beta (THRB) gene has two iso-
 Different mutations in the TRβ gene have   on the course and outcome of pregnancy in   A study of a large Azorean family har-  pregnancy. Their affected offspring had increased risk of small-  forms, THRB1, which is widely distributed, and THRB2, which
 varying effects on the receptor function   women with RTH and even fewer reports   boring the R243Q TRβ gene mutation found   for-gestational age and poor postnatal weight gain.   is limited to the cochlea, retina, and pituitary gland. These two
 that affected pregnant women carrying unaf-  Conclusions: Clinical heterogeneity due to THRB mutations   splice variants differ in their amino-terminal ends, but both
 Table 1. Thyroid function tests and treatment during pregnancy  fected fetuses had a threefold to fourfold   cannot be explained by the variant rs2596623. Mothers and   include the same functional ligand-binding domain in the
 Date  weeks of pregnancy   TSH (Iu/ml)  fT4 (pmol/l)  fT3 (pmol/l)  pTu treatment  higher miscarriage rate [1]. In addition, the   newborns with THRB mutations seem to be at increased risk   carboxyl-terminal region, where most of the disease-causing
 20/10/2014  0  0.58  43.3  –  None  unaffected infants born to RTH mothers   for certain complications, such as gestational hypertension   mutations that have been identified to date are located [1].
 26/02/2015  13   0.03  54  19  None  had significantly lower birth weight com-  and poor intrauterine and postnatal growth. However, these   Previous in vitro studies using pituitary cell lines defined a basal
 25/03/2015  17   0.2  29.9  –  150 mg  pared to infants with RTH. Their postnatal   issues are usually mild, suggesting that routine intervention   promoter region in the THRB2 isoform. While assessing the
 TSH level was suppressed in all cases. This   to regulate thyroid hormone levels may not be warranted in   promoter’s function in vivo, Jones and co-workers [2] identified
 21/04/2015  20   0.17  36.2  9.2  450 mg  these patients.
 situation indicates that the normal fetuses                          a conserved 600 base-pair intronic region that appears to act
 20/05/2015  25   0.26  31.5  8.8  450 mg
 were exposed to high maternal TH levels,           IMAJ 2018; 20: 679–686  as an enhancer, modifying expression of the THRB2 isoform in
 25/06/2015  30   0.7  28.9  9.1  450 mg  inappropriate to their genotype, and devel-  KEY WORDS:  genetic disease of the thyroid, monogenic thyroid disease,   pituitary and retinal cells. Alberobello and colleagues [3] pro-
 23/07/2015  34   1.01  32  –  450 mg  thyroid hormone receptor, thyroid hormone receptor beta
 oped fetal hyperthyroidism. Moreover, in a
 16/08/2015  37   1.36  28.5  7.8  450 mg  recent study, intrauterine exposure to high   (THRB) mutations, thyroid hormone resistance  *The study was performed in fulfillment of the research requirements
 FT3 = free triiodothyronine, FT4 = free thyroxine, PTU = propylthyouracil, TSH = thyroid stimulating hormone  TH levels was shown to cause persistent   toward an MD degree at the Hebrew University–Hadassah School of
                                                                        Medicine, Jerusalem, Israel
 710                                                                                                            679
   12   13   14   15   16   17   18   19   20   21   22